Patient response to new digital components in the electronic informed consent (eIC) process is overwhelmingly positive, with nearly three-fourths of respondents to a recent survey saying they find enhanced eIC more personable, engaging and informative.
Read More
Drugs for cognitively and functionally normal people who have the pathophysiologic changes of Alzheimer’s disease (AD) could be approved on a single biomarker outcome, according to the FDA’s new draft guidance on drug development for early AD.
Read More
This week’s Pipeline features a phase 1 trial approval for cyclin E overexpressing cancers, a phase 2 trial start for treatment-resistant depression and an FDA approval for a pneumococcal conjugate vaccine.
Read More